1. Home
  2. HOUR vs IFRX Comparison

HOUR vs IFRX Comparison

Compare HOUR & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hour Loop Inc.

HOUR

Hour Loop Inc.

HOLD

Current Price

$1.99

Market Cap

72.5M

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.05

Market Cap

86.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOUR
IFRX
Founded
2015
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.5M
86.0M
IPO Year
2022
2017

Fundamental Metrics

Financial Performance
Metric
HOUR
IFRX
Price
$1.99
$1.05
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.50
AVG Volume (30 Days)
42.1K
909.6K
Earning Date
11-12-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
$140,790,433.00
$73,729.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,075.42
P/E Ratio
$83.79
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.10
$0.71
52 Week High
$6.90
$2.77

Technical Indicators

Market Signals
Indicator
HOUR
IFRX
Relative Strength Index (RSI) 45.97 42.44
Support Level $1.99 $1.00
Resistance Level $2.11 $1.12
Average True Range (ATR) 0.11 0.09
MACD 0.02 -0.01
Stochastic Oscillator 46.81 36.09

Price Performance

Historical Comparison
HOUR
IFRX

About HOUR Hour Loop Inc.

Hour Loop Inc is a technology-enabled consumer products company that uses machine learning and data analytics to design, develop, market, and sell products. Hour Loop predominantly operates through online retail channels such as Amazon, Walmart, and Hourloop.com. The Company, as an Internet marketplace seller, sells products in multiple categories, including home/garden decor, toys, kitchenware, apparel, and electronics. It has only one segment, which is online retail (e-commerce).

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: